Menu
Anzor’s commitment to science has resulted in promising breakthroughs in the fight against endocrine and metabolic diseases. Rigorous animal studies have revealed its remarkable efficacy, showcasing its potential to revolutionize treatments. Anzor efforts offer new hope for millions affected by hormonal and metabolic diseases.
Anzor’s comprehensive research and development have shown that interventions utilizing fibroblast growth factors (FGF) significantly impact animal models of endocrine and metabolic diseases.
Based on extensive research and development, Anzor has demonstrated significant effects of fibroblast growth factor (FGF) based interventions in animal models of endocrine and metabolic diseases. In an obesity animal model, an FGF-based peptide ligand produced marked weight loss over a 30-day period. Additionally, in an animal model of chronic kidney disease, an FGF peptide ligand significantly enhanced kidney function.
Low molecular weight peptides offer better diffusion, lower immunogenicity, and less toxic metabolites compared to full-length proteins.
Peptides can be engineered for improved specificity and reduced off-target effects.
Anzor has published extensively over the years in leading peer-reviewed journals. Published patents and patent applications protect the results of the company’s research efforts.
X-linked hypophosphatemia (XLH) is a rare genetic disorder characterized by low blood phosphate levels due to mutations in the PHEX gene, which leads to excessive production of fibroblast growth factor 23 (FGF23), resulting in increased renal phosphate wasting and impaired bone mineralization.
Cancer | Dermatological Disorders | Limb Abnormalities | Mitochondrial Diseases
Dwarfism Syndromes | Developmental Disorders | Skeletal Dysplasia
Nature Reviews Drug Discovery. 2025 January: Gaozhi Chen, Moosa Mohammadi, et.al.
